Overview

A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

Status:
Terminated
Trial end date:
2018-10-02
Target enrollment:
Participant gender:
Summary
This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug lanabecestat in participants with early Alzheimer's disease dementia at the time of entry into study I8D-MC-AZES.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Eli Lilly and Company
Collaborators:
AstraZeneca
Eli Lilly and Company